How Long Does Vyvanse Work? Effects & Timeline

Vyvanse (lisdexamfetamine) provides symptom control for roughly 13 to 14 hours after a single morning dose, with effects typically beginning about one to two hours after swallowing the capsule and peaking around three hours later. That duration is longer than what most other extended-release stimulants deliver, and it comes from an unusual design: Vyvanse is an inactive prodrug that your body has to disassemble before it does anything. That slow, built-in conversion step is the reason the drug’s timeline feels so different from older stimulants, and understanding the conversion helps explain why the experience can shift depending on who is taking it and what else is going on.

Why Vyvanse Takes Longer to Kick In

Vyvanse is not amphetamine. It is lisdexamfetamine, a molecule made by bonding the amino acid lysine to d-amphetamine. In that bonded form, it has no stimulant activity. Only after the lysine is stripped off does d-amphetamine become available in the bloodstream. That stripping happens inside red blood cells, where enzymes called peptidases chop the lysine away. In lab studies using whole human blood, the intact prodrug disappeared with a half-life of about 1.6 hours, and roughly 82 percent of it was gone after four hours.¹ The process is not instant, and it is rate-limited: no matter how much Vyvanse you swallow, the red blood cells can only convert it so fast.

This conversion step adds a built-in delay compared to taking d-amphetamine directly. In a head-to-head pharmacokinetic study, the rise in blood amphetamine levels after a Vyvanse dose had about a 0.6-hour longer lag time and reached peak concentrations roughly an hour later than an equivalent dose of plain d-amphetamine.² In practical terms, most people notice Vyvanse starting to work within one to two hours of taking it, compared to the faster onset many experience with immediate-release stimulants.

Peak Effects and the Middle of the Day

After the prodrug has been substantially converted, blood levels of d-amphetamine hit their peak around three hours post-dose. A Phase I study in healthy adults measured a median time to peak concentration of 3.0 hours after a single Vyvanse dose, with a peak level averaging about 80 ng/mL.³ This is the window when symptom control is strongest: focus sharpens, impulsivity drops, and the sense of mental “quiet” that people with ADHD describe is at its most noticeable.

Because the prodrug conversion is gradual rather than all-at-once, many users describe a smoother ramp-up than what they felt on immediate-release medications. That smoothness matters. A pronounced early spike in amphetamine levels can feel like a jolt, sometimes accompanied by a racing heart or mild euphoria, followed by a sharper crash when levels fall. Vyvanse’s flatter curve means the peak is not dramatically higher than the levels that follow it, which tends to make the midday hours feel more even.

How the Afternoon and Evening Play Out

After peaking, d-amphetamine levels decline gradually. The elimination half-life measured in that same Phase I study was about 10.4 hours, meaning it takes roughly that long for half the drug to leave your system.³ But you do not feel the drug for 10-plus hours after the peak; you feel it while concentrations remain above the threshold where it is therapeutically useful. Clinical data show that threshold is maintained for at least 13 hours in children and 14 hours in adults.⁴ That is longer than what has been reported for any other long-acting amphetamine formulation.

For someone taking a morning dose at 7 a.m., this means noticeable symptom control through 8 or 9 p.m. A clinical review described Vyvanse as having a smooth onset of action, exerting its effects for up to 13 hours, and potentially producing fewer rebound symptoms than some alternatives.⁵ “Rebound” is the flare of irritability, hyperactivity, or emotional sensitivity that some people experience as a stimulant wears off. Because Vyvanse’s decline is gradual rather than cliff-like, rebound tends to be milder, though it is not eliminated entirely for everyone.

What the Wear-Off Actually Feels Like

The transition from “on” to “off” is something users track closely, and it is worth separating what happens pharmacologically from what it feels like day to day. Pharmacologically, d-amphetamine levels start a slow decline after hour three, but remain clinically meaningful for many hours. The subjective experience, though, varies. Some people feel a clear transition point around hours 10 to 12 where focus drops, motivation dips, and tasks feel harder. Others describe a more gradual dimming with no sharp boundary.

The wear-off period can bring specific symptoms worth watching for:

Fatigue: A wave of tiredness that hits in the late afternoon, sometimes described as feeling “hit by a wall.”
Appetite return: Vyvanse suppresses appetite for most people, and hunger often comes roaring back as the drug fades, leading to overeating in the evening.
Emotional sensitivity: Some people notice they become more easily frustrated or tearful during the tail end of the dose.
Difficulty with tasks: Executive function tasks that felt manageable at midday become harder again, which can be discouraging if you still have work to finish.

These wear-off effects are not side effects in the traditional sense. They are the return of baseline symptoms, sometimes sharpened by contrast with the medicated hours. Strategies like timing the dose earlier, eating a protein-rich meal before it fades, or reserving less demanding tasks for late evening can help soften the transition.

Why Duration Varies from Person to Person

Thirteen to 14 hours is a clinical average, not a guarantee. Individual differences in metabolism, body composition, and genetics mean that real-world duration can range from roughly 10 hours to well beyond 14. Several factors shape where you fall on that spectrum.

Body size and metabolic rate play a role, though not as straightforwardly as people assume. A larger person does not necessarily burn through the drug faster; what matters more is how efficiently their red blood cells convert the prodrug and how quickly their kidneys clear the resulting amphetamine. The rate of that red blood cell conversion is remarkably consistent across people. Even in blood samples from donors with sickle cell disease, the half-life of the prodrug was about 1.3 hours, compared to roughly 1.1 hours in healthy donors, a difference unlikely to be clinically meaningful.⁶ This consistency is one of the drug’s design strengths: unlike formulations that rely on pH-dependent coatings or liver enzymes, the conversion mechanism does not vary wildly between individuals.

Urine pH, however, can shift how fast amphetamine leaves the body. Acidic urine speeds up excretion, potentially shortening how long you feel the drug. Alkaline urine does the opposite, and a review noted that alkalizing agents may prolong the exposure to d-amphetamine released from Vyvanse.⁷ In practice, this means people who drink large amounts of citrus juice, take vitamin C supplements, or eat a very high-protein diet (which acidifies urine) could experience a somewhat shorter duration. Conversely, antacids or a heavily plant-based diet could extend it. The effect is real but usually modest unless you are consuming large amounts of acidifying or alkalizing substances.

Stomach Acid Medications and Vyvanse

A common concern is whether acid-reducing drugs like omeprazole interfere with Vyvanse. Because some other extended-release stimulants rely on pH-sensitive coatings to control drug release in the gut, changes in stomach acidity can disrupt their timing. Vyvanse works differently. Its active ingredient is released not by a coating dissolving in the stomach but by enzymes inside red blood cells, so stomach pH has little direct bearing on the conversion process.

A pharmacokinetic study confirmed this. When Vyvanse was taken alongside omeprazole, the peak concentration and total drug exposure were essentially unchanged. The median time to peak remained at 3 hours with or without the acid-blocker.⁸ The same study found that a different extended-release amphetamine formulation was more affected by omeprazole, with a noticeable shift in the timing of peak blood levels for a majority of subjects taking it. If you take a proton pump inhibitor or H2 blocker for acid reflux, Vyvanse’s timeline should remain stable in a way that not all stimulant formulations can match.

Food also has less impact than many people expect. Vyvanse can be taken with or without a meal. Eating does not meaningfully change the total amount of d-amphetamine your body absorbs; it may slightly delay the onset by slowing how quickly the capsule contents reach the intestines, but the difference is typically on the order of minutes, not hours. Some people find that taking it with breakfast reduces stomach discomfort, which is a reasonable enough reason to eat first even without a pharmacokinetic argument.

How Vyvanse Compares to Other Long-Acting Stimulants

The most common comparison is between Vyvanse and extended-release mixed amphetamine salts (the generic of Adderall XR). Both are amphetamine-based, both aim for all-day coverage, and both are widely prescribed. But their mechanisms of extended release are fundamentally different. Adderall XR uses a bead-based system with two releases: an immediate pulse and a delayed pulse. Vyvanse uses the prodrug conversion already described. The result is a different curve shape and, for many people, a different subjective experience.

In a crossover classroom study comparing the two in children with ADHD, investigators rated about 74 percent of children on Vyvanse as much improved or very much improved, compared with 72 percent on extended-release mixed amphetamine salts. Those overall numbers are close, but the proportion rated “very much improved” was higher on Vyvanse: 32 percent versus 16 percent.⁹ This is a single study and the ratings were made by investigators (not blinded patients), so the difference should be interpreted with some caution. But it aligns with what clinicians often report anecdotally: Vyvanse tends to feel smoother, with fewer complaints about a “second kick” or midday trough.

The prodrug design also makes Vyvanse more resistant to manipulation. Crushing, snorting, or dissolving the capsule contents does not release d-amphetamine any faster, because the rate-limiting step is enzymatic, not mechanical. Preclinical research confirmed that the drug’s conversion to d-amphetamine is performed by peptidases associated with red blood cells and is rate-limited.¹⁰ You cannot shortcut the process by changing how you take it, which is part of why the drug was originally developed as an abuse-deterrent stimulant option.

Does Vyvanse Lose Effectiveness Over Time?

Tolerance is a persistent worry for anyone on a long-term stimulant. The concern is understandable: if the drug works well for the first six months and then gradually stops working, you are left chasing higher doses or switching medications. The evidence on this is more reassuring than most people expect.

The best long-term data come from methylphenidate (a related but different stimulant), where researchers followed patients for up to 10 years. When doses were adjusted only for body growth, the medication remained effective for the vast majority. Only 3 out of 108 patients lost their therapeutic response without an obvious explanation, a rate of about 2.7 percent.¹¹ True pharmacological tolerance, where the brain adapts to the drug’s presence and stops responding, appears to be rare. What people often interpret as tolerance is something else: increased life demands, worsening sleep, stress, or simply forgetting how bad things were before medication.

Vyvanse-specific long-term studies have generally shown sustained efficacy over 12 months and beyond, though the data spans fewer years than the methylphenidate literature. If you feel the drug losing its punch, the first step should be evaluating sleep, diet, exercise, and life stressors rather than assuming your brain has adapted. A conversation with your prescriber about whether the dose still matches your body weight and daily demands is also worth having before concluding that tolerance has set in.

Vyvanse for Binge Eating Disorder

Vyvanse is the only stimulant medication approved by the FDA for treating moderate-to-severe binge eating disorder in adults. The timeline of its effects in this context is the same as for ADHD: it starts working within a couple of hours and provides coverage through most of the day. The relevant question for binge eating is whether it meaningfully reduces the number of binge episodes, and the answer across clinical trials is a clear yes.

A meta-analysis of placebo-controlled trials found that Vyvanse at doses of 50 and 70 mg per day produced large reductions in binge eating days per week, with results reaching strong statistical significance.¹² A maintenance trial looked at whether the benefit held up after initial treatment. Among people who had responded well to Vyvanse, those switched to placebo relapsed at a rate of about 32 percent, compared with under 4 percent of those who stayed on the drug.¹³ That is a dramatic difference, and it suggests the drug’s effect on binge eating is not just an early-phase placebo response.

The mechanism behind this benefit is not fully understood. It likely involves the same dopamine and norepinephrine signaling that helps with ADHD focus, applied to the impulsive component of binge eating. Some researchers suspect the appetite suppression common to all amphetamines plays a supporting role, though appetite suppression alone does not explain the large and sustained reduction in binge episodes. It is worth noting that Vyvanse is not approved for weight loss, and prescribing it for that purpose alone is off-label and not supported by the binge eating trial data.

Timing Your Dose for Real Life

Knowing that the drug lasts roughly 13 to 14 hours gives you a framework, but translating that into a dosing schedule requires some personal calibration. Most prescribers recommend taking Vyvanse first thing in the morning, and for good reason: a 7 a.m. dose means coverage through 8 or 9 p.m., which maps well onto a typical work or school day plus the evening wind-down. Take it much later and you risk lying awake at midnight with a still-active stimulant in your system.

Some people, particularly those whose most important tasks happen later in the day (evening students, shift workers), experiment with taking the dose later in the morning. This can work, but it requires accepting that the onset window overlaps with less demanding morning hours and that the tail end extends further into the night. Sleep disruption from a late dose is common and tends to erode the drug’s benefit over time, since poor sleep worsens every ADHD symptom the medication is meant to treat.

If 13 hours of coverage is not enough and your symptoms resurface in the evening, the usual clinical approach is a small supplemental dose of immediate-release amphetamine in the late afternoon. This is sometimes called a “booster.” It is a separate prescription, not a second Vyvanse capsule, and the dose is typically much smaller. Doubling up on Vyvanse to extend coverage is discouraged because the prodrug’s built-in ceiling means you will not get a meaningful second wave; you will just increase the overall peak.

One underappreciated nuance is that the clock starts when you swallow the capsule, not when you feel it working. That one-to-two-hour onset delay means your first hour of the day is largely unmedicated. Some people develop a routine of taking the capsule the moment they wake up, then using that hour for low-stakes activities like showering and breakfast, reserving demanding work for after the drug has kicked in. Small adjustments like this often make more difference to the daily experience than chasing a higher dose.